Latest Contraceptives News

Page 1 of 1
Mayne Pharma reports mixed early FY26 results with strong prescription growth in Women’s Health and improved Dermatology margins, while strategic reviews and litigation loom.
Ada Torres
Ada Torres
22 Dec 2025
Mayne Pharma’s innovative oral contraceptive NEXTSTELLIS® has secured reimbursement under Australia’s Pharmaceutical Benefits Scheme, making it significantly more affordable and broadening contraceptive options nationwide.
Victor Sage
Victor Sage
29 Sept 2025
Shine Justice Ltd reported a 4.4% rise in FY25 revenue to $204.4 million, alongside major legal settlements and leadership changes, signaling renewed growth momentum.
Victor Sage
Victor Sage
28 Aug 2025
Mayne Pharma has clarified why it did not disclose an FDA Untitled Letter to the market despite sharing it with its scheme bidder, reaffirming compliance with ASX rules amid recent share price volatility.
Victor Sage
Victor Sage
22 May 2025
Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.
Victor Sage
Victor Sage
14 May 2025
Mayne Pharma has addressed a sharp share price decline following the public release of an FDA Untitled Letter, confirming no undisclosed material information and reaffirming compliance with ASX rules.
Ada Torres
Ada Torres
14 May 2025